An estimation of the 5-year cost effectiveness of adding leflunomide to a strategy of conventional disease modifying antirheumatic drugs in patients with rheumatoid arthritis.

被引：0
|
作者：
Maetzel, A
Strand, A
Tugwell, P
Wells, G
Bombardier, C
机构：
来源：
ARTHRITIS AND RHEUMATISM | 2000年 / 43卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
466
引用
收藏
页码：S144 / S144
页数：1
相关论文
共 50 条
  • [1] Cost effectiveness of adding leflunomide to a 5-year strategy of conventional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
    Maetzel, A
    Strand, V
    Tugwell, P
    Wells, G
    Bombardier, C
    [J]. ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2002, 47 (06): : 655 - 661
  • [2] Leflunomide combined with conventional disease-modifying antirheumatic drugs or biologics in patients with rheumatoid arthritis
    Combe, Bernard
    [J]. JOINT BONE SPINE, 2006, 73 (06) : 587 - 590
  • [3] Cost effectiveness analysis of disease modifying antirheumatic drugs in rheumatoid arthritis
    Manathip Osiri
    Pirom Kamolratanakul
    Andreas Maetzel
    Peter Tugwell
    [J]. Rheumatology International, 2007, 27 : 1063 - 1069
  • [4] Cost effectiveness analysis of disease modifying antirheumatic drugs in rheumatoid arthritis
    Osiri, Manathip
    Kamolratanakul, Pirom
    Maetzel, Andreas
    Tugwell, Peter
    [J]. RHEUMATOLOGY INTERNATIONAL, 2007, 27 (11) : 1063 - 1069
  • [5] Cost Effectiveness Analysis of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis. A Systematic Review Literature
    Benucci, Maurizio
    Saviola, Gianantonio
    Manfredi, Mariangela
    Sarzi-Puttini, Piercarlo
    Atzeni, Fabiola
    [J]. INTERNATIONAL JOURNAL OF RHEUMATOLOGY, 2011, 2011
  • [6] Shared epitope and long-term effectiveness of disease modifying antirheumatic drugs (DMARD) in patients with rheumatoid arthritis.
    Suarez-Almazor, ME
    Maksymowych, W
    Russell, AS
    [J]. ARTHRITIS AND RHEUMATISM, 1999, 42 (09): : S132 - S132
  • [7] Lipid abnormalities in patients with early rheumatoid arthritis. Effect of disease modifying antirheumatic drugs
    Georgiadis, AN
    Lourida, ES
    Elisaf, M
    Tselepis, AD
    Drosos, AA
    [J]. CHEMISTRY AND PHYSICS OF LIPIDS, 2004, 130 (01) : 76 - 76
  • [8] COST-EFFECTIVENESS OF BIOLOGICS COMPARED TO CONVENTIONAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS FOR TREATMENT OF RHEUMATOID ARTHRITIS IN FINLAND
    Joensuu, J. T.
    Aaltonen, K. J.
    Aronen, P.
    Sokka, T.
    Puolakka, K.
    Tuompo, R.
    Korpela, M.
    Vasala, M.
    Ilva, K.
    Nordstrom, D.
    Blom, M.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A648 - A648
  • [9] Conventional disease-modifying antirheumatic drugs to treat rheumatoid arthritis
    Rath, T.
    Sander, O.
    Rubbert, A.
    [J]. DRUG DEVELOPMENT RESEARCH, 2011, 72 (08) : 657 - 663
  • [10] Cost-effectiveness of Anbainuo plus methotrexate compared to conventional disease-modifying antirheumatic drugs for rheumatoid arthritis patients in China
    Tian, Feng
    Wen, Zhenhua
    Li, Jingyang
    Luo, Xiaowen
    Deng, Li
    Zhang, Liang
    He, Jingyun
    Yao, Fangling
    Liao, Zheng
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (14)
12345